Clinical Scorecard: Efficacy of Intravenous Cyclophosphamide and Mycophenolate Mofetil for Treating Pediatric Lupus Nephritis in Resource-Constrained Environments

At a Glance

Key Highlights

• 55% of children with cSLE develop lupus nephritis.
• CYC and MMF are first-line agents according to EULAR and KDIGO guidelines.
• Complete renal response rates range from 50% to 78.8% at 24 months.
• Treatment switching is common due to inadequate response or adverse effects.
• Limited pediatric-specific comparative data available.

Guideline-Based Recommendations

Diagnosis

• Confirm lupus nephritis via renal biopsy or clinical/laboratory evidence of active renal involvement.

Management

• Induction therapy with CYC or MMF, combined with corticosteroids and supportive care.

Monitoring & Follow-up

• Assess renal function and proteinuria regularly to evaluate treatment response.

Risks

• Potential for treatment switching due to inadequate clinical response or adverse effects.

Patient & Prescribing Data

Children with cSLE and LN treated at a tertiary referral hospital.

CYC administered at 0.5–1.0 g/m² monthly for 6 months; MMF at 600–1,200 mg/m²/day.

Clinical Best Practices

• Utilize KDIGO criteria for assessing renal response.
• Monitor for adverse effects and adjust treatment as necessary.
• Consider adjunctive therapies for severe or refractory cases.

References

• EULAR/ACR SLE Classification Criteria
• KDIGO Guidelines